Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: Is there a lead-time bias?

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 4, 2007, Pages 485-492

  Huo, Teh Ia ^a,b   Huang, Yi Hsiang ^a,b   Chiang, Jen Huei ^a,b   Wu, Jaw Ching ^a,b   Lee, Pui Ching ^b   Chi, Chin Wen ^a,b   Lee, Shou Dong ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Arterial embolization; Hepatocellular carcinoma; Liver cirrhosis; Model for endstage liver disease; Percutaneous injection therapy

Indexed keywords

ACETIC ACID; ALCOHOL;

AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SCORING SYSTEM; SURVIVAL; SURVIVAL RATE; THERAPY DELAY; TUMOR VOLUME;

ACETIC ACID; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; ETHANOL; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LIVER NEOPLASMS; MALE; SURVIVAL RATE;

EID: 34147132307     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600931402     Document Type: Article

References (46)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23.
2. Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P, et al. Hepatocellular carcinoma. Ann Oncol 2001;12:161-72.
3. Kawasaki S, Makuuchi M, Miyagawa S, Kakazu T, Hayashi K, Kasai H, et al. Results of hepatic resection for hepatocellular carcinoma. World J Surg 1995;19:31-4.
4. Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993;105:488-94.
5. Grazi GL, Cescon M, Ravaioli M, Ercolani G, Gardini A, Del Gaudio M, et al. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics: evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 2003;17(Suppl 2):119-29.
6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
7. Ryder SD, Rizzi PM, Metivier E, Karani J, Williams R. Chemoembolizaton with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut 1996;38:125-8.
8. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918-28.
9. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
10. Shijo H, Okazaki M, Higashihara H, Koganemaru F, Okumura M. Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization. Am J Gastroenterol 1992;87:1154-9.
11. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
12. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-8.
13. Orlando A, D'Antoni A, Camma C, Albanese M, Livraghi T, Torzilli G, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am J Gastroenterol 2000;95:2921-7.
14. Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2003;17(Suppl 2):103-10.
15. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-7.
16. Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M, Maltinti G, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: analysis of prognostic factors in 105 Western patients. Cancer 1995;76:1737-46.
17. Kotoh K, Sakai H, Sakamoto S, Nakayama S, Satoh M, Morotomi I, et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol 1994;89:194-8.
18. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. Scand J Gastroenterol 2002;37:350-5.
19. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27:67-72.
20. Ohnishi K, Nomura F, Ito S, Fujiwara K. Prognosis of small hepatocellular cacinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases. Hepatology 1996;23:994-1002.
21. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Treatment of nodular hepatocellular carcinoma larger than 3 cm with ultrasound-guided percutaneous acetic acid injection. Hepatology 1996;24:1379-85.
22. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 2003;38:770-8.
23. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-61.
24. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-6.
25. Huo TI, Lee SD. Management of inoperable hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:S272-8.
26. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8.
27. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005;242:36-42.
28. Bialecki ES, Di Bisceglie AM. Clinical presentation and natural course of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:485-9.
29. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005;100:1995-2004.
30. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
31. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-30.
32. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
33. The Cancer of the Liver Italian Program (CLIP) investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:840-5.
34. Huang YS, Chiang JH, Wu JC, Chang FY, Lee SD. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 2002;97:1223-7.
35. Huang YH, Wu JC, Chau GY, Lui WY, King KL, Chiang JH, et al. Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients. Eur J Gastroenterol Hepatol 1999;11:315-21.
36. Huo TI, Huang YH,Wu JC, Chiang JH, Lee PC, Chang FY, et al. Sequential transarterial chemoembolization and percutaneous acetic acid injection therapy versus repeated percutaneous acetic acid injection for unresectable hepatocellular carcinoma: a prospective study. Ann Oncol 2003;14:1648-53.
37. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42.
38. Ohto M, Yoshikawa M, Saisho H, Ebara M, Sugiura N. Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients. World J Surg 1995;19:42-6.
39. Llovet JM, Sala M. Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:505-13.
40. Huo T, Huang YH, Wu JC, Chiang JH, Lee PC, Chang FY, et al. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary locoregional therapy for unresectable hepatocellular carcinoma: a prospective survey. Aliment Pharmacol Ther 2004;19:1391-8.
41. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. The United Network For Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
42. Olthoff KM, Brown RS Jr, Delmonico FL, Freeman RB, McDiarmid SV, Merion RM, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. Liver Transpl 2004;10(Suppl 2):A6-22.
43. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004;4(Suppl 9):114-31.
44. Wang VS, Saab S. Liver transplantation in the era of the model for end-stage liver disease. Liver Int 2004;24:1-8.
45. Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther 2003;17:1563-9.
46. Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, et al. Evaluation of the increase in the model for end-stage liver disease (MELD) score over time as a prognostic predictor in patients with advanced liver cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42:826-32.